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Photodynamic therapy of C3H mouse mammary carcinoma
with haematoporphyrin di-ethers as sensitizers
J.F. Evensen, S. Sommer, C. Rimington & J. Moan
Institutefor Cancer Research, The Norwegian Radium Hospital, 0310 Oslo 3, Norway.
Summary Haematoporphyrin di-ethers were synthesized and tested as sensitizers for photodynamic therapy
of C3H/Tif mammary tumours in mice. Growth curves of the tumours were determined by measuring the
tumour volume. The animals were given 25 mg porphyrins kg-1 body weight i.p. and 24h later exposed to
135 Jcm-2 of 630 nm light at a fluence rate of 150 mWcm-2. The sensitizing efficiency of the ethers was
measured in terms of the increase in growth time of the treated tumours, as compared with that of untreated
controls, needed to reach a volume 5 times larger than that at the time of the treatment. This sensitizing
efficiency increased with decreasing polarity, i.e. in the order di-methyl ether, di-ethyl ether, di-propyl ether, di-
butyl ether and di-amyl ether. Haematoporphyrin di-amyl ether was more efficient than haematoporphyrin
derivative and insignificantly less efficient than photofrin II (DHE). This was true for sensitization of both
tumours and normal tissue.
Haematoporphyrin derivative, HpD, and its purified version
Photofrin II, also called DHE, are porphyrin preparations
that are being tested clinically for use as sensitizers in
photodynamic cancer treatment (PDT). So far several
promising reports on the efficacy of this treatment have been
published (Dougherty, 1985 and references cited therein). The
complete chemical composition of the active fraction of HpD
and DHE has not been finally resolved, although it has been
proposed that it consists of dihematoporphyrin ethers or
esters (Bonnett & Berenbaum, 1983; Dougherty, 1984; Kessel
et al., 1985). Neither is it known why certain components of
these porphyrin preparations are selectively retained by
tumours compared with many normal tissues. It has been
assumed that polarity and aggregation properties may play
important roles (Moan, 1986). This led us to prepare and test
several porphyrin di-ethers with chromatographic properties,
and hence polarities, in the range of those of the tumour-
localizing fraction of HpD and DHE. These compounds have
a known chemical structure and with one exception we
found that they could be purified to the degree desired. It is
a major drawback for the clinical and experimental use of
HpD and DHE that they contain so many chromato-
graphically different components (Bonnett et al., 1980; Moan
& Sommer, 1984). Even though many of these components
may be isomeric structures of the same porphyrin, one would
prefer to use a single, well defined compound of known
structure.
Materials and methods
Photofrin II (DHE, lot PC 218) and Photofrin I was
obtained from Photomedica, Inc., Raritan, N.J. Hemato-
porphyrin (Hp) di-hydrochloride from Koch Light was used
in the preparation of HpD, according to the method of
Lipson et al. (1961). This product was similar, both with
respect to chromatographic properties and sensitizing
efficiency, to Photofrin I from Photomedica. Since the sen-
sitizing efficiency of Hp was to be tested, we ensured by
chromatographic analysis (RP 18 column eluted with a
water/methanol gradient and both absorbance and
fluorescence detection as described by Sommer et al., 1984)
that the chemical was of high purity. It was found to be
>94% pure and to contain <1% unknown material and
<55% hydroxyetylvinyldeuteroporphyrin, the most common
contaminant in Hp preparations.
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Hp di-ethers were prepared by a modification of the
procedures described by Kuster and Deihle (1913) and
Willstatter and Fischer (1913): Hemin (Sigma Chem. Co.)
was dissolved in HBr/acetic acid (specific gravity 1.14, 33%)
and allowed to stand for 4h. After removal of the solvent
under reduced pressure, methanol, ethanol, propanol,
butanol, amyl alcohol or hexanol was added and allowed to
react for 24h at 50°C. The resulting porphyrins have ether
groups at the 2- and 4-positions of the ring and ester groups
at the 6- and 7-positions (see Figure 1). The latter groups
were removed by treatment with KOH in tetrahydrofuran.
The methyl-, ethyl-, propyl-, and butyl-ethers were >90%
pure as analyzed by HPLC. Separate runs of each ether were
performed, as well as runs of mixtures of all of them to
determine their relative retention times. The relation of the
retention time to the number of carbon atoms in the
substituting alcohol was practically linear (Rimington et al.,
1986). In the chromatogram of the amyl-ether two slightly
separated peaks appeared (ret. times 30 and 31 min,
respectively) related to the fact that commercial amyl alcohol
is a mixture of -87% iso-amyl alcohol and 13% amyl
alcohol. By the present method it was not possible to
prepare the hexyl-ether more than 50% pure. Two major
porphyrin contaminants of unknown structure (ret. times 24
CH3
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Figure 1 The chemical structure of haematoporphyrin and those
of its ethers tested in the present work: R1 =H:
haematoporphyrin (Hp); R2 = -CH3: Hp di-methyl ether; R3 =
-C2H5: Hp di-ethyl ether; R4=-C3H7: di-propyl ether; R,5=
-C4Hq: Hp di-butyl ether; R6 = -C5H1I : Hp di-amyl ether and
R7= -C6H13: Hp di-hexyl ether.
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and 28 min, respectively, as compared with 35 min for the
hexyl ether) always appeared. Details of the chemical
procedures and of the purity testing are published separately
(Rimington et al., 1986).
The porphyrins were brought into sterile, neutral, iso-
tonic, aqueous solution at a concentration of2.5 mgml -l. First
they were dissolved in 0.1 M NaOH, then HCl and NaCl
were added to make the solutions neutral and isotonic.
HPLC revealed no changes during 2 weeks storage at 4°C.
The absorption spectra of all porphyrins used in the present
work were recorded, using low concentrations in the mobile
HPLC phase. The ratio of the absorbance at 630 nm to that
in the Soret band was within 6% similar for all of these
porphyrins. Spectral data are given elsewhere (Rimington et
al., 1986).
Animals and tumour system
Female C3D2F,/Bom mice (C3H/Tif y x DBA/2S, G.
Bomholt Gaard, Ry., Denmark) 7-8 weeks old were
challenged with a spontaneous C3H/Tif mammary carcinoma
by serial transplantation. Tumour for inoculation was
obtained by sterile dissection of flank tumours. Macro-
scopically viable tumour tissue was minced with a pair of
scissors and forced through sterile needles of decreasing
dimension (19-, 21- and 23-gauge). Finally 0.02 ml of the
suspension was injected s.c. on the dorsal side of the foot of
the right hind limb by a 25-gauge needle. The mice were
assessed regularly and the tumour size measured along 3
orthogonal diameters (D,, D2, D3) every second day, using
calipers. The volume was calculated assuming spheroidal
geometry V=(7r/6)DID2D3. When the tumours reached
75-100mm3 the mice were injected i.p. with 25mg porphyrin
kg-1 body weight and irradiated 24h later. In the cases of
HPD and Photofrin II this time between injection and
irradiation was found to give an optimal tumour response.
After irradiation each tumour was measured 3 times a
week and the results for each porphyrin were pooled to give
a mean growth curve. In the regressing phase the size of all
tumours on each day was averaged and the mean volume
was plotted +1 s.e. (vertical bars; Figure 2). Once steady
regrowth was established, the analysis was changed: the time
taken to reach fixed sizes was determined for each mouse
and the mean time was plotted +1 s.e. (horizontal bars;
Figure 2). The use of the average time to reach a fixed
endpoint (horizontal averaging) avoids ambiguities due to
different growth rates which may result from variable latency
periods as discussed by others (Begg, 1980).
The tumour response was evaluated as the tumour growth
time required for a tumour to reach a volume 5 times that at
the treatment day. The exponential regrowth phase was
evaluated as the tumour doubling time at the point when the
tumour was 5 times the treatment volume. These calculations
were based on growth curves for each individual mouse
(Begg, 1980).
The normal tissue response was evaluated measuring the
thickness of a treatment induced oedema in the right hind
limb of mice without tumours. These mice were given exactly
the same photodynamic treatment as those bearing tumours.
After irradiation, the thickness (T1) of the treated and (T.)
of the untreated foot was measured 3 times a week for at
least 30 days. The normal tissue response was calculated as
(7T/IT) - 1. Each treatment group contained 5 mice.
Irradiation
Unanaesthetized mice were placed in Lucite jigs with the
tumour-bearing leg loosely fixed with tape without impairing
the blood flow to the foot. The tumour was then exposed to
red light from a Rhodamine 6G dye laser (Spectra Physics
375) pumped by an argon ion laser (Spectra Physics 164).
The dye laser was tuned at 630+5 nm by use of a
monochromator (Jarrel Ash) and the wavelength was
regularly checked. The laser beam was defocused by means
of a microscope ocular ( x 12). The fluence rate at the
position of the tumour was measured by means of a
calibrated thermopile (YSI Kettering model 65A Radiometer)
and maintained at 150 mWCcm-2. The exposure time was
15 min corresponding to an exposure of 135 Jcm-2.
Results
The retention time of the Hp di-ethers of an RP18 column
increased with increasing length of the carbon chain of the
residues R1 7 at positions 2 and 4 of the porphyrin (Figure
1; Table I).
In the absence of porphyrins and light the tumours grew
exponentially with doubling time of -2 days. Treatment
with porphyrins without light had no effect on tumour
growth. Treatment with light alone (15 min, 150mW) had an
insignificant effect on tumour growth and so had treatment
with Hp, Hp di-methyl ether and Hp di-ethyl ether combined
with light (Figure 2; Table I). Hp di-propyl-, Hp di-butyl-
and Hp di-amyl ethers showed increasing efficiencies in this
order, while Hp di-hexyl ether was somewhat less efficient
than Hp di-amyl ether (Figures 2 and 3; Table I). As
expected, Photofrin II was more efficient than HpD, but not
significantly more efficient than Hp di-amyl ether (Table 1).
The same was also true for normal tissue reactions (Figure
4). The reaction with Photofrin II as the sensitizer was quite
strong since all the treated mice without tumours lost feet
-8 days after irradiation. Mice treated with Hp di-amyl
ether and light showed a similarly strong reaction of their
normal tissue at day 1-8 after the irradiation, but all of them
gradually healed (Figure 4).
Table I Relative efficacy of haematoporphyrin derivatives on tumour growth time and tumour doubling time
Retention
time on Time to 5 x treatment Doubling time in
RP18 column volume (days) regrowth phase (days) Number of
Porphyrin species (min) mean+s.e. mean +s.e. mice
Control (-porphyrin, -light) 4.1 +0.1 2.0+0.1 68
Control (-porphyrin, +light) 5.7+0.6 2.2+0.1 16
HP 6.0 & 6.5a 5.3+0.4 2.1+0.1 16
HpD 6-40 11.4+0.8 2.2+0.2 26
PII 6-40 15.9+1.1 2.7+0.3 15
Hp di-methyl ether 15 4.3+0.2 1.9+0.1 2
Hp di-ethyl ether 20 4.7+0.4 2.0+0.2 14
Hp di-propyl ether 26 6.1+0.5 2.3+0.1 11
Hp di-butyl ether 29 8.4+0.8 2.2+0.2 7
Hp di-amyl ether 30 & 31b 14.6+1.0 2.3+0.1 16
Hp di-hexyl ether 35 12.2+0.7 1.9+0.2 8
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Figure 2 Growth curves of tumours in mice after treatment with 25mg sensitizer kg-' body wt and, 24h later, exposure for
15 min to 150mW of light at 630nm. Panel a: * * untreated controls; ] OL haematoporphyrin; 0-0 HpD; 0-0
Photofrin II. Panel b: K O> Hp di-methyl ether; * * Hp di-ethyl ether. Panel c: V V Hp di-propyl ether; V V Hp di-
butyl ether. Panel d: A A Hp di-amyl ether; /A Hp di-hexyl ether. Bars: s.e.
None of the treatments were found to have any significant
effect on the tumour doubling time in the regrowth phase
(Table I).
Discussion
The least polar of the Hp-ethers tested in the present work
showed a significant efficiency as sensitizers for photo-
dynamic tumour therapy in the present model system. Since
the polarity of a compound generally decreases with
increasing retention time on a reversed phase HPLC column,
the results indicate that for this family of porphyrins the
efficiency as sensitizers for PDT increases with decreasing
polarity (Figure 3). The reason why our preparation of the
Hp di-hexyl ether has a lower sensitizing efficiency than
might be expected is probably because it contains significant
amounts (50%) of porphyrin impurities with higher polarity
than that of the hexyl ether, while the other ether
preparations were more than 90% pure. It is also possible
that the hexyl-ether which has a low polarity and, therefore,
supposedly a low solubility in water, forms large aggregates
in aqueous solutions which are of a nature that prevents
tumour uptake.
Hp di-amyl ether was equally efficient as Photofrin II in
tumour photosensitization (Table I), Photofrin II, Hp di-amyl
ether and to a smaller extent HpD, had significant photo-
sensitizing effects also on normal tissue as shown by the
induced oedema. Similar oedema may also occur in tumours.
Therefore, the effect on tumours for the first few days after
irradiation may be underestimated in our measurements.
This is also indicated by the fact that in some cases the
volume of treated tumours apparently increased more than
that of untreated controls during early days after the
irradiation (Figure 2a).
The treatment undoubtedly gives rise to damage of the
normal tissue in which the tumour grows. This probably
affects tumour growth in the early phase after the treatment.
However, since the doubling time in the regrowth phase of
treated tumours was almost the same as the doubling time of
untreated tumours (Figure 2; Table I), we conclude that no
large change in the tumour bed occurred.
Although a fluence rate of 150mWcm 2 might be
expected to be too low to give hyperthermic effects to the
tumour when applied for only 15min (Gomer et al., 1986)
our data indicate that irradiation of unsensitized tumour
leads to a slight retardation of the growth (Table I). Thus, it
cannot be excluded that hyperthermia contributes slightly to
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Figure 3 The growth delay of treated tumours with different
Hp-ethers as sensitizers. Growth delay is given as the difference
between the times needed for treated tumours to reach a volume
5 times larger than that at the time of irradiation and the
corresponding time for untreated tumours.
the observed effects. This will be checked further, since it has
been shown that moderate hyperthermia may potentiate the
effect of PDT (Christensen et al., 1984; Waldow &
Dougherty, 1985). However, it is unlikely that slight hyper-
thermia plays a role that is different for the different
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Figure 4 Response of normal tissue (mouse foot) to treatment
with HpD *-*, 0-0 Photofrin II and A-, Hp di-amyl
ether followed by light exposure. Conditions as described for
Figure 2. The point marked * indicates that at this time the
treated feet of all the mice given Photofrin II were lost.
sensitizers tested in the present work, and that their relative
sensitizing effects would be different under conditions where
hyperthermic effects were completely absent. Fluence rates
much higher than 150 mWcm-2 have been applied in many
experimental and clinical studies for the obvious reason to
make the exposure time as short as possible.
The most polar sensitizers tested (Hp, Hp di-methyl- and
Hp di-ethyl ether) had little or no sensitizing effect (Table I).
This is in agreement with the results of Dougherty (1983)
who found practically no response of SMT-F mammary
tumours in mice to treatment with pure Hp and light.
The present work was supported by The Norwegian Cancer Society
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